Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the introduction and expanded uptake of new drugs, including therapies from Novartis, Alizyme, Solvay, and Astellas, will drive the market to treat irritable bowel syndrome to $1.2 billion in 2014.

The new Pharmacor report entitled Irritable Bowel Syndrome finds that market growth will be driven by the introduction of high-priced therapies, most notably the 5-HT receptor modulators, including Novartis's Zelnorm/Zelmac (tegaserod), Alizyme's renzapride, Solvay's cilansetron, and Astellas Pharma's Nasea OD (ramosetron). The report also finds that the market to treat the disease is relatively untapped and that significant commercial opportunity exists for agents with novel mechanisms of action.

"There are a number of shortcomings among the five classes of current therapies available to treat irritable bowel syndrome -- these classes are the 5-HT receptor modulators, laxatives, antidiarrheals, antispasmodics, and antidepressants," said Cindy Mundy, Ph.D., analyst at Decision Resources, Inc. "Most patients are still treated with older drugs that offer limited efficacy such as fiber, bulk laxatives, and antidiarrheals. As a result, there remains considerable opportunity for drug developers to introduce therapies with increased efficacy and novel mechanisms of action."

About Irritable Bowel Syndrome

Irritable bowel syndrome is the most common of the 25 recognized functional gastrointestinal diseases. Experts estimate that nearly 20% of the world's population suffers from a combination of altered bowel function such as diarrhea, constipation, or alternation of the two as well as the abdominal pain that is the hallmark of the disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs currently on the market and in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Health Plans Adapted Rapidly to a Post-Hurricane Louisiana Healthcare Market

View Now